Example: Heart Attack

Clinical Trials on Anaplastic Thyroid Cancer

Total 69 results

NCT02726503

Completed

Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer
NCT04574817

Not yet recruiting

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Conditions: Anaplastic Thyroid Cancer
NCT03085056

Recruiting

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer
NCT01774279

Recruiting

interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)

Conditions: Anaplastic Thyroid Cancer
NCT02516774

Withdrawn

A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers

Conditions: Anaplastic Thyroid Cancers
NCT00280852

Completed

Review of Multimodality Management of Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer
NCT03122496

Active, not recruiting

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Conditions: Metastatic Anaplastic Thyroid Cancer
NCT01701349

Withdrawn

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer
NCT02244463

Recruiting

A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer; Thyroid Cancer
NCT03565536

Unknown status

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Conditions: Thyroid Cancer, Anaplastic
NCT02688608

Recruiting

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer
NCT00507429

Terminated

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer
NCT01240590

Completed

A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)

Conditions: Solid Tumor; Anaplastic Thyroid Cancer
NCT02152137

Active, not recruiting

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer
NCT02657369

Terminated

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Conditions: Thyroid Carcinoma, Anaplastic
NCT04739566

Recruiting

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

Conditions: Thyroid Gland Anaplastic Carcinoma
NCT00603941

Terminated

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Conditions: Anaplastic Thyroid Cancer
NCT00126568

Terminated

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer; Recurrent Thyroid Cancer
NCT01236547

Active, not recruiting

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Conditions: Thyroid Gland Anaplastic Carcinoma
NCT04420754

Recruiting

Study of AIC100 in Relapsed/Refractory Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer; Relapsed/Refractory Poorly Differentiated Thyroid Cancer
NCT04238624

Recruiting

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Conditions: Anaplastic Thyroid Cancer; Thyroid Cancer; BRAF Gene Mutation; BRAF Mutation-Related Tumors
NCT04675710

Not yet recruiting

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Conditions: Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma
NCT04552769

Recruiting

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Conditions: Thyroid Cancer; Anaplastic Thyroid Cancer; Undifferentiated Thyroid Cancer
NCT02289144

Withdrawn

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

Conditions: Metastatic Anaplastic Thyroid Cancer; Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
NCT03975231

Recruiting

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Conditions: BRAF NP_004324.2:p.V600E; BRAF V600K Mutation Present; Thyroid Gland Anaplastic Carcinoma